Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

TEVA-DEFERASIROX - Health Canada Drug Approval Details

Approvals/Health Canada/TEVA-DEFERASIROX

Authorized

STANDARD

TEVA-DEFERASIROX

teva canada limited🇨🇦 Health Canada

Approval Date: Jul 4, 2025
Approval ID: 30a0d44ae24d82c4
Company: teva canada limited
Type: Standard

Approval Details

Approval Id: 30a0d44ae24d82c4
Drug Approval Canada Name: TEVA-DEFERASIROX
Product Name: TEVA-DEFERASIROX
Status: Cancelled Post Market
Status Date: 2020-06-07
Original Market Date: 2017-06-26
Din: 02407965
Drug Class: Human
Dosage Form: Tablet For Suspension
Route Of Administration: Oral
Schedule: Prescription
Ahfs: 64:00.00
Atc Original: V03AC03 DEFERASIROX
Atc Name: v 03 ac 03
Aig Number: 0151733002
Company Name: teva canada limited
Company Address: 30 Novopharm Court, Toronto, Ontario, Canada, M1B 2K9

Active Ingredients

DEFERASIROX

250 MG

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

30a0d44ae24d82c4

Type

Standard

Back to Health Canada Approvals